Extranodal Extension on Sentinel Lymph Node Dissection: Why Should We Treat It Differently? Audrey Choi MD, Matthew Surrusco MD, Samuel Rodriguez MD, Khaled.

Slides:

Advertisements

Similar presentations

Baptist Health System General Surgery Residency Program

Advertisements

Neo-adjuvant Chemotherapy for Breast Cancer

Tumor Size and Sentinel Node Procedure A. Ph. MAKAR, MD, Ph.D. R. Van Den Broecke, MD, Ph.D. Depart of Senology & Gynaecologic Oncology The Middelheim.

Chemotherapy Prolongs Survival for Isolated Local or Regional Recurrence of Breast Cancer: The CALOR Trial (Chemotherapy as Adjuvant for Locally Recurrent.

Obesity at Diagnosis Is Associated with Inferior Outcomes in Hormone Receptor Positive Breast Cancer 1 The Impact of Body Mass Index (BMI) on the Efficacy.

Neoadjuvant Chemotherapy in Malignant Peripheral Nerve Sheath Tumors Elizabeth Shurell, M.D., M.Phil. UCLA General Surgery Resident Research Fellow, Division.

Kevin S. Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Associate Professor of Surgery Harvard.

Breast Cancer in Pregnancy

Role of Nodal Irradiation in Breast Cancer

 DISCUSSION Number of resected lymph nodes in esophageal surgery has been previously discussed as for its probable impact on patients’ survival [4]. The.

An update for Illinois Nurses Elizabeth A. Peralta, MD The Breast Center at SIU Springfield, IL May 2011.

Giuliano Pre-SSO mins ASCO Z mins

Sentinel Lymph Node Biopsy in Melanoma

Breast Cancer Tumor Board Chair Harold Burstein, MD, PhD Faculty Jennifer Bellon, MD Mehra Golshan, MD.

SHELBY ADDISON NEAL, MD MENTORS: WILLIAM T. CREASMAN, MD WHITNEY S. GRAYBILL, MD, MS Lymph-Vascular Space Invasion (LVSI) in Uterine Corpus Cancer What.

Sentinel Lymph Node Dissection (SND)

Giving Induction Radiation in Addition to Chemotherapy Is Not Associated with Improved Survival of NSCLC Patients with Operable Mediastinal Nodal Disease.

Clinical Utility of Combidex in Various Cancers

Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.

Prognostic factors for breast cancer survival in affluent and deprived areas Jasmina Stefoski-Mikeljevic.

Hot topics in breast radiotherapy Mark Beresford.

Ductal Carcinoma in situ

Neoadjuvant Chemotherapy for Ca Breast CY Choi UCH.

Surgery Journal Club By : Ahmad Zahmatkesh Mohammadreza Nazemian.

Suggested guidelines for appropriate patient selection for patients undergoing Accelerated Partial Breast Irradiation at DMC. Tonya Echols Cole, MD.

Ethnic Disparities in Early Breast Cancer Management among Asian Americans and Pacific Islanders Rebecca P. Gelber, MD, MPH Department of Medicine, University.

SYB Case 2 By: Amy. History 63 y/o female History of left breast infiltrating duct carcinoma s/p mastectomy in 1996 and chemotherapy ER negative, PR negative,

Background Sentinel lymph node biopsy has been recently introduced in the clinical setting because it is highly accurate in predicting the lymph node status.

A Phase II Study to Evaluate the Safety and Toxicity of Sparing Radiation to the Pathologic N0 Side of the Neck in Squamous Cell.

Metabolic Syndrome and Recurrence within the 21-Gene Recurrence Score Assay Risk Categories in Lymph Node Negative Breast Cancer Lakhani A et al. Proc.

Background  Reports of long-term survivors (≥5 years) of locally advanced esophageal cancer (LAEC) have focused mainly on HRQL or GI symptoms  Only.

A Glimpse of the Science Behind the American Cancer Society Access to Care Campaign Impact of Being Uninsured or Underinsured on Individuals with Cancer.

11th Biennial Meeting of the International Gynecologic Cancer Society 11th Biennial Meeting of the International Gynecologic Cancer Society Semih Gorgulu,

Clinical Trials Evaluating the Role of Sentinel Node Resection in Patients with Early-Stage Breast Cancer Krag DN et al. Proc ASCO 2010;Abstract LBA505.

The Treatment of the Axilla in the North of England Cancer Network. Henry Cain ST7 North Tyneside.

TREATMENT Mastectomy -traditionally, treatment of breast ca has been surgical -19 century, surgical treatment : local excision ~ total mastectomy : radical.

How are Auckland Surgeons Managing the Axilla? E Whineray Kelly, O Pellet, L Neave, J Harman, R Harman. Auckland Breast Cancer Study Group.

Radical Mastectomy is no longer the standard Improved adjuvant and neoadjuvant therapy Chemotherapy Endocrine therapy Radiation treatment Reconstruction.

The treatment of metastatic squamous cell carcinoma (SCCA) of the anal canal: A single institution experience P. Pathak, B. King, A. Ohinata, P. Das, C.H.

Ductal Carcinoma in Situ with Microinvasion: Prognostic Implications, Long-term Outcomes, and Role of Axillary Evaluation Rahul R. Parikh, MD 1, Bruce.

Snyder D, Heidel RE, Panella T, Bell J, Orucevic A University of Tennessee Medical Center – Knoxville Departments of Pathology, Surgery, and Medicine BREAST.

on behalf of the ACOSOG Z4032 Investigators

Adjuvant High-Dose-Rate Brachytherapy Alone for Stage I/II Endometrial Adenocarcinoma using a 4-Gray versus 6-Gray Fractionation Scheme Marie Lynn Racine,

Evidence for a Survival Benefit Conferred by Adjuvant Radiotherapy in a Cohort of 608 Women with Early-stage Endometrial Cancer O. Kenneth Macdonald 1,

Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2009 – December 31, 2009.

Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2011 – December 31, 2011 Compiled by Lynn Day, RN BSN CCM CCRP.

The impact of smoking on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB Nadine A. Jackson, Charles S.

Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2010 – December 31, 2010 Compiled by Lynn Day, RN BSN CCM CCRP.

Basis and Outcome of Axillary Dissection for Node Negative Axilla Gurpreet Singh Dept. Of Surgery P.G.I.M.E.R. These Power Point presentations are free.

Annals of Oncology 24: 2206–2223, 2013 R3 조영학

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer Slideset on: Piccart-Gebhart M, Procter M, Leyland- Jones B, et al. Trastuzumab.

Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer Anna Bill-Axelson, M.D., Lars Holmberg, M.D., Ph.D., Mirja Ruutu, M.D., Ph.D., Michael.

ABSTRACT Purpose This retrospective review was conducted to determine if delay in the start of radiotherapy after conservative breast surgery had any detrimental.

MA.17R: Reduced Risk of Recurrence With Extending Adjuvant Letrozole Beyond 5 Yrs in Postmenopausal Women With Early-Stage Breast Cancer CCO Independent.

The New trends in the Management of Breast Cancer 謝渙發桃園縣醫師公會監事怡仁綜合醫院副院長教育部部定助理教授國防醫學院外科學系臨床教授.

Mamounas EP et al. Proc SABCS 2012;Abstract S1-10.

Comparison between Pathologic Characteristics of Her2 Negative and Positive Breast Cancer in a Single Cancer Center in Jordan DR Majdi A. Al Soudi, MD,

Recommendation for axillary lymph node dissection in women with early breast cancer and sentinel node metastasis: A systematic review and meta-analysis.

Prognostic significance of tumor subtypes in male breast cancer:

R. Michelle Sarin, MD Mentor: Jeffrey Fowler, MD

HER2 and estrogen receptor status drive decisions regarding the use of neoadjuvant chemotherapy Neil Love, MD1, Kimberly L Blackwell, MD2, Eleftherios.

Prognosis of younger patients in non-small cell lung cancer

Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results.

徐慧萍1 羅竹君1,2 郭耀隆1 李國鼎1 國立成功大學醫學院附設醫院外科部1 國立成功大學醫學院臨床醫學研究所2

Untch M et al. Proc SABCS 2010;Abstract P

Stamatia Destounis, MD, FACR, FSBI, FAIUM

Martin M et al. Proc SABCS 2012;Abstract S1-7.

THE LANCET Oncology Volume 19, No. 1, p27–39, January 2018

Presentation transcript:

Extranodal Extension on Sentinel Lymph Node Dissection: Why Should We Treat It Differently? Audrey Choi MD, Matthew Surrusco MD, Samuel Rodriguez MD, Khaled Bahjri MD, MPH, Naveen Solomon MD, Carlos Garberoglio MD, Sharon Lum MD, Maheswari Senthil MD

Background »Completion axillary lymph node dissection has remained the standard of care for sentinel lymph node metastasis »ACOSOG Z0011 trial ~T1-T2, breast conservation surgery (BCS) with radiation, underwent sentinel lymph node dissection (SLND) with 1-2 positive SLN ~Randomized to completion axillary lymph node dissection (ALND) or no further surgery ~27% of patients in ALND group had additional nodal burden ~No difference in locoregional recurrence and overall survival at median follow up time (6.3 years)

Background »ACOSOG Z0011 showed selected patients with limited axillary nodal burden on SLND can avoid added morbidity of ALND ~Patients with extranodal extension (ENE) on pathology were excluded from the study »Current standard of care is to proceed with ALND if ENE is found on SLND ~Significance of ENE identified on SLND is not well defined

Objective »To determine the impact of ENE detected on sentinel lymph node dissection on: ~Axillary nodal burden ~Disease recurrence ~Overall survival

Design »Retrospective cross-sectional study, prospectively collected database »Included patients with breast cancer undergoing SLND at Loma Linda University Medical Center » »Statistical analysis ~Adjusted and unadjusted analyses of covariates associated with disease recurrence and overall survival

Results All patients with SLND N=655 No SLN metastasis N=478 (73.0%) SLN metastasis without ENE N=124 (70.1%) SLN metastasis with ENE N=53 (29.9%) SLN metastasis present N=177 (27.0%)

Patient demographics Value Age (years) Median57 (26-86) Tumor size in situ4/177 (2.3%) T196/177 (54.2%) T255/177 (31.3%) T312/177 (6.8%) T43/177 (1.7%) Missing7/177 (3.9%) Receptor Status ER+155/177 (87.6%) PR+141/177 (80.0%) Her2/Neu+25/174 (14.4%) Value Grade I31/177 (17.5%) II66/177 (37.3%) III65/177 (36.7%) IV3/177 (1.7%) Missing7/177 (3.9%) Adjuvant therapy Systemic119/167 (71.3%) Radiation108/166 (65.1%)

Non-SLN metastasis NSLN metastasis N=26 (57.8%) SLN metastasis without ENE N=124 (70.1%) SLN metastasis with ENE N=53 (29.9%) NSLN metastasis N=37 (44.0%) No further disease N=47 No ALND N=40 No further disease N=19 No ALND N=8 ALND N=84 ALND N=45 SLN metastasis present N=177

Increased axillary nodal burden P = 0.01 *

Type of recurrence +ENE »ENE associated with increased disease recurrence -ENE

Disease recurrence Adjusted analyses of covariates associated with disease recurrence »4 times the odds of experiencing disease recurrence if +ENE on SLND »Trend toward significance on adjusted analysis

Overall survival »Over 7 times the odds for decreased survival if +ENE on SLND »Statistically significant after controlling for other factors Adjusted analyses of covariates associated with overall survival

Conclusions »Extranodal extension on sentinel lymph node dissection was associated with: ~Increased axillary nodal burden ~Increased disease recurrence ~Associated with poor survival outcome »Extranodal extension on SLND should be considered a poor prognostic factor »Extranodal extension found on SLND still warrants completion axillary lymph node dissection

Thank you!